activates the mTORC1 pathway through an EP4/cAMP/PKA-and EP1/Ca 2ϩ -mediated mechanism in the human pancreatic carcinoma cell line PANC-1.
association remain poorly understood. A number of factors, such as the proinflammatory state associated with excess adiposity, as well as the elevated levels of growth hormones, i.e., insulin and insulin-like growth factor type 1 (IGF-1), are implicated (21) . Compensatory high levels of insulin during obesity-associated insulin resistance are known to upregulate hepatic IGF-1 synthesis and suppress IGF-binding protein, leading to increased bioavailable IGF-1 (10) . The elevated levels of insulin/IGF-1 may contribute to cancer development by activating insulin and IGF-1 receptors and the downstream phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex 1 (mTORC1) cascade, a key signaling module in the regulation of cell growth and survival (26, 41) . In accordance with this notion, type 2 diabetes, hyperinsulinemia, and increased circulating IGF-1 are established risk factors for pancreatic and other types of cancers (17, 48) . Additionally, the IGF-1/Akt/mTORC1 pathway has been shown to be important in promoting proliferation of pancreatic cancer cells (45) and, recently, has been implicated in the anticancer effects of caloric restriction and the procancer effects of an obesity-inducing diet on mouse models of pancreatic cancer (28) . Triggered by growth factors (e.g., IGF-1), mTORC1 is activated through the canonical PI3K/Akt module and can phosphorylate a number of substrates involved in protein synthesis and cell growth, such as ribosomal protein S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E-binding protein (4E-BP1) (26) . Therefore, the insulin/IGFmTOR axis may, at least in part, account for the link between obesity and pancreatic cancer.
In addition to systemic hormonal changes, increasing attention has focused on the local and systemic effects of inflammation. Obesity is recognized as a chronic inflammatory state, with leukocyte infiltration into adipose and other tissues accompanied by increased local and systemic proinflammatory mediators such as cytokines and prostaglandins (21, 39) . Chronic inflammation has long been associated with cancer development and progression (30) . Our previous study also showed that oral administration of nimesulide, a nonsteroidal anti-inflammatory drug, significantly delayed the progression of Kras-driven early pancreatic neoplasia in a conditional mouse model (11) . A critical player in the obesity-inflammation-cancer axis is prostaglandin E2 (PGE 2 ), a key inflammatory lipid mediator generated by cyclooxygenase enzymes (COX-1 and -2), the best-characterized targets of nonsteroidal anti-inflammatory drugs (32) . Overexpression of COX-2 and elevated levels of PGE 2 are often observed in human cancers, including pancreatic cancer, as well as in obese individuals (9, 35, 47, 49) . Secreted by tumor cells or infiltrating inflammatory cells, PGE 2 , through activation of its receptors and downstream signaling, may promote cell proliferation, survival, migration, invasion, angiogenesis, inflammation, and immune evasion (14, 18, 37) . PGE 2 exerts its biological functions through binding to one of the four subtypes of G protein-coupled receptors (GPCRs), EP 1 , EP 2 , EP 3 , and EP 4 (50) . Previously, we showed that the growth-promoting effects of PGE 2 on pancreatic cancer cells are mediated by EP 2 and/or EP 4 (12) , both of which are coupled with G protein ␣ s (G␣ s ), which is known to stimulate cAMP formation and, subsequently, activate protein kinase A (PKA) (7) .
Overall, the mechanisms underlying obesity-promoted pancreatic cancer are most likely to be multifaceted and interrelated. Links between critical signaling pathways deserve more attention. In particular, a potential cross talk between the PGE 2 /EP/cAMP and IGF-1/Akt/mTOR pathways in pancreatic cancer has not been explored. It has been demonstrated in other cell systems that cAMP or PKA can lead to activation of mTORC1 (3, 22) . Therefore, by activating EP receptors, PGE 2 may stimulate mTORC1 and potentiate its growth-promoting action. We have uncovered a novel cross talk between PGE 2 signaling and the mTORC1 pathway in pancreatic cancer cells. We further investigated the mechanisms through which PGE 2 can stimulate mTORC1 and, potentially, augment the protumorigenic effects of insulin/IGF-1. Since PGE 2 signaling and the IGF-1/Akt/mTORC1 pathway are overactivated in obesityassociated cancers, this novel cross talk may be of great importance in elucidating the tumor-promoting effects of obesity and inflammation in pancreatic and other types of cancers. , and GAPDH MAb (catalog no. 2118). PGE2, forskolin, H-89, butaprost, the EP4 agonist CAY10580, the EP2 antagonist PF-04418948, the EP4 antagonist ONO-AE3-208, ionomycin, and BAPTA-AM were purchased from Cayman Chemical (Ann Arbor, MI); rapamycin from Santa Cruz Biotechnology (Santa Cruz, CA); EP 1 small interfering RNA (siRNA; catalog no. L-005711, ONTARGETplus human PTGER1 siRNA-SMARTpool) from GE Dharmacon (Lafayette, CO); and recombinant human IGF-1 from SigmaAldrich (St. Louis, MO).
MATERIALS AND METHODS

Antibodies
Cell culture and treatments. The human cancer cell lines AsPC-1, BxPC-3, Capan-2, HPAF-II, MIA PaCa-2, and PANC-1 (pancreatic cancer), PC-3 (prostate cancer), MCF-7 (breast cancer), and DLD-1 and SW480 (colon cancer) were obtained from the American Tissue Type Culture Collection. MIA PaCa-2 and PANC-1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% FBS and 1ϫ penicillin-streptomycin-glutamine (Life Technologies, Grand Island, NY) and cultured at 37°C and 10% CO 2. AsPC-1, BxPC-3, Capan-2, HPAF-II, PC-3, MCF-7, DLD-1, and SW480 cells were maintained in RPMI 1640 medium supplemented with 10% FBS and 1ϫ penicillin-streptomycin-glutamine (Life Technologies) and cultured at 37°C and 5% CO 2. For Western blot analysis, cells were seeded in six-well plates. After serum starvation for 18 h, cells were treated as indicated.
Western blotting. After treatments, cells were harvested and lysed in lysis buffer (1ϫ Tris buffer, pH 7.4, 1% Triton X-100, and 0.25% sodium deoxycholate) supplemented with protease and phosphatase inhibitor cocktails (Thermo Scientific, Rockford, IL). Forty micrograms of proteins [quantified using a BCA protein assay kit (Thermo Scientific)] were loaded onto 10% Mini-PROTEAN TGX precast gels (Bio-Rad Laboratories, Hercules, CA). The proteins were electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked and incubated with primary antibodies according to the manufacturer's recommendations. After incubation with secondary antibodies, proteins were detected by ECL reagents (Thermo Scientific) and exposed to CL-XPosure X-ray films (Thermo Scientific).
Intracellular cAMP measurement. Cells were seeded in six-well plates or 35-mm dishes and then serum-starved. After treatments, cells were lysed in 0.1 M HCl (150 l per well). The lysates were centrifuged at 1,000 g and 4°C for 10 min. cAMP levels in the cell lysates were then measured by a cAMP enzyme immunoassay kit (Cayman Chemical) following the manufacturer's instructions. cAMP levels were normalized to the protein concentrations of the samples.
Intracellular Ca 2ϩ concentration measurement. Cells were seeded on coverslips. After serum starvation, the coverslips were incubated with 5 M fura 2-AM diluted in prewarmed Hanks' balanced salt solution (HBSS) containing 20 mM HEPES (pH 7.4) for 1 h at 37°C. Coverslips were then mounted in an experimental chamber (0.5 ml volume) placed on the stage of an inverted microscope (Axio Observer.A1). The chamber was perfused (1 ml/min) at 37°C with buffered HBSS. At selected times, the perfusion fluid was changed to HBSS containing agonists (PGE2). Ratio (340-nm excitation to 380-nm excitation) images were obtained every second by a digital camera (AxioCam MRm) attached to the microscope, which was operated with associated software (AxioVision, all components from Carl Zeiss, Thornwood, NY). Intracellular Ca 2ϩ concentration is proportional to the ratio of excitation at 340 nm to excitation at 380 nm. In some experiments, cells were plated onto coverslips that fit inside cuvettes, which in turn were loaded into a temperature-controlled fluorometer (Hitachi). At selected times, agonist was introduced into the cuvette. Ratio values for the entire cuvette were determined as described above.
siRNA transfection. Cells were seeded in six-well plates and incubated overnight in Dulbecco's modified Eagle's medium with 10% FBS. Transfection of siRNA was carried out on the following day with Lipofectamine RNAiMAX reagent (Life Technologies) following the manufacturer's recommendations. Cells were incubated for an additional 3 days and then serum-starved and stimulated with PGE2.
Quantitative reverse-transcription PCR. Relative transcript expression levels of EP1, EP2, EP4, and IL-23 were determined by quantitative RT-PCR (RT-qPCR) using a SYBR Green-based method. Briefly, the PureLink RNA Mini Kit (Life Technologies) was used to extract total RNA from cells. Reverse transcription was performed with the iScript reverse-transcription supermix (Bio-Rad Laboratories) using 1 g of total input RNA. The synthesized cDNA samples were used as templates for the following real-time PCR analysis. All reactions were performed using the Bio-Rad iQ5 system, and the amplifications were done using the iTaq Universal SYBR Green Supermix (Bio-Rad). Gene-specific oligonucleotide primers for EP1, EP2, EP4, and IL-23A (IL-23, ␣-subunit p19) and internal reference ACTB (␤-actin) or RNA18S5 (RNA, 18S ribosomal 5) are as follows: 5=-ACCTTCTTTGGCGGCTCTC-3= (forward) and 5=-CCAACACCAGCATTGGGCT-3= (reverse) for EP1 (exons 2 and 3), 5=-GCTCCTTGCCTTTCACGATTT-3= (forward) and 5=-AG-GATGGCAAAGACCCAAGG-3= (reverse) for EP2 (exons 1 and 2), 5=-CGCTCGTGGTGCGAGTATT-3= (forward) and 5=-AGGGGTCTAGGATGGGGTTC-3= (reverse) for EP4 (exons 2 and 3), 5=-CACTAGTGGGACACATGGATCT-3= (forward) and 5=-GGTGGATCCTTTGCAAGCAG-3= (reverse) for IL-23A (exons 1 and 2), 5=-GCACAGAGCCTCGCCTTT-3= (forward) and 5=-TATCATCATCCATGGTGAGCTGG-3= (reverse) for ACTB (exons 1 and 2), and 5=-AGTCCCTGCCCTTTGTACACA-3= (forward) and 5=-CGATCCGAGGGCCTCACTA-3= (reverse) for RNA18S5. The relative mRNA transcript levels are calculated using the 2 Ϫ⌬⌬Ct method (29) to determine the fold change in indicated genes normalized to ACTB or RNA18S5.
Cytokine array. PANC-1 cells were seeded in six-well plates and then serum-starved. Cells were incubated in culture medium (2 ml) with or without PGE 2 and IGF-1, alone or in combination. Cell culture supernatants collected after 24 h of incubation were profiled using the Human Cytokine Array Statistical analyses. Values are means Ϯ SD. To determine statistical significance, one-way ANOVA and two-tailed Student's t-tests were performed assuming unequal variances. P Ͻ 0.05 was considered significant.
RESULTS
PGE 2 activates mTORC1 in human pancreatic cancer cells.
PANC-1 cells have been used extensively as a model system to study the effects of growth factors on the biological behavior of human pancreatic cancer cells. To determine whether PGE 2 stimulates mTOR signaling in pancreatic cancer cells, PANC-1 cells were treated with PGE 2 , and then mTORC1 activation was assessed by Western blot analysis of phosphorylation levels of downstream molecules. As shown in Fig. 1, A and B, PGE 2 dose-and time-dependently induced the phosphorylation of S6rp at Ser 235/236 , which correlated with the increased Thr 389 phosphorylation of p70S6K, a major mTORC1 target upstream of S6rp. These effects were robust after 15 min of stimulation and observed at 0.1 M PGE 2 .
Although Ser 235/236 phosphorylation of S6rp can also be accomplished by p90S6K independently of mTORC1, p90S6K activation assessed by Ser 380 phosphorylation was unchanged in response to PGE 2 treatment (Fig. 1B) . Also, phosphorylation of ERK, a key regulator of p90S6K, was not increased by PGE 2 in these cells (Fig. 1A) . Furthermore, phosphorylation of S6rp at Ser 240/244 , known to be a p70S6K-specific site (1, 44), was markedly induced by treatment with PGE 2 (Fig. 1, B 4 /cAMP/PKA pathway. As a first step to examine the mechanism(s) by which PGE 2 induces mTORC1 activation in PANC-1 cells, we determined the effects of PGE 2 on intracellular cAMP levels. A representative dose-response curve is shown in Fig. 2A . A half-maximal increase was seen at 0.09 M, and maximal effects were obtained at ϳ1 M PGE 2 . Notably, PGE 2 was effective at submicromolar concentrations, suggesting that the responses were mediated by specific binding to the EP receptors. We verified that treatment of these cells with PGE 2 increased the phosphorylation of CREB (Fig. 1, A and B) , which is known to be positively regulated by PKA, the activation of which is dependent on cAMP.
Next, we determined whether the elevation of the intracellular levels of cAMP is sufficient to induce mTORC1 activation. Exposure to the adenylate cyclase activator forskolin induced a marked accumulation of cAMP in MIA PaCa-2 and PANC-1 cells (Fig. 2B) . Importantly, forskolin mimicked the effect of PGE 2 on S6rp phosphorylation in both cell lines (Fig.  2C) , supporting the idea that cAMP is involved in this cross talk. Also, the effect of forskolin was blocked in cells preincubated with H-89 (Fig. 2C) , a preferential inhibitor of PKA.
Among the four subtypes of GPCRs for PGE 2 , EP 2 and EP 4 are known to couple to G␣ s and, thus, are responsible for stimulating cAMP production via activation of adenylate cyclase (50) . To determine the contribution of EP 2 and EP 4 , receptor agonists and antagonists were utilized. As shown in Fig. 3A , PGE 2 -induced cAMP accumulation was blocked by the EP 4 antagonist ONO-AE3-208, but not by the EP2 antagonist PF-04418948, in PANC-1 cells. Besides, an EP 4 agonist (CAY10580), rather than an EP 2 agonist (butaprost), markedly increased cAMP production in these cells (Fig. 3B) , indicating the importance of EP 4 in mediating cAMP responses in PANC-1 cells.
We next used pharmacological approaches to further substantiate a link between cAMP and mTORC1. The EP 4 agonist CAY10580 promoted mTORC1 activation, as assessed by S6rp phosphorylation (Fig. 4A) . Importantly, PGE 2 -activated S6rp phosphorylation (at Ser 235/236 or Ser 240/244 ) was prevented by the specific EP 4 antagonist ONO-AE3-208 (Fig. 4B) . These results reinforce the notion that PGE 2 -induced cAMP accumulation and subsequent responses are mainly mediated by the EP 4 receptor in PANC-1 cells.
The cAMP-dependent PKA is a central target of cAMP. Therefore, we used the PKA inhibitor H-89 to test whether PGE 2 -stimulated mTORC1 activation is PKA-dependent. Pretreatment of cells with 5 M H-89 attenuated baseline and PGE 2 -activated S6rp phosphorylation (Fig. 4C) , indicating a role for PKA in the cross talk between PGE 2 signaling and the mTORC1 pathway. This finding is in agreement with previous results showing that PGE 2 -induced activation of p70S6K and S6rp paralleled an increase in the phosphorylation of CREB, a substrate of PKA (Fig. 1) . ) (Fig. 4C) . These results suggest that, besides cAMP, PGE 2 may activate an additional pathway leading to mTORC1 activation. Ca 2ϩ signaling has been implicated in the regulation of mTORC1 activation independently of PI3K/Akt (15, 31, 34) . Consequently, PGE 2 might exert some of its cAMP-independent effects through activation of EP 1 receptors, which couple to G␣ q and, thereby, promote phospholipase C-mediated formation of diacylglycerol and inositol trisphosphate, second messengers leading to PKC activation and Ca 2ϩ mobilization, respectively (19) . Initially, we examined whether PGE 2 induces Ca 2ϩ mobilization in PANC-1 cells. In agreement with this hypothesis, we found that addition of PGE 2 to fura 2-loaded PANC-1 cells induced a rapid and transient increase in intracellular Ca 2ϩ levels in PANC-1 cells (Fig. 5A ). This microscopy-based measurement allowed us to monitor the Ca 2ϩ response in individual cells and revealed that ϳ62% of the cells (8 of 13) were responsive to PGE 2 to varying extents (see representative traces in Fig. 5A) .
Additionally After treatments, cell lysates were collected and subjected to immunoblotting with phosphorylated ribosomal protein S6 kinase (p-p70S6K and p-p90S6K), phosphorylated S6 ribosomal protein (p-S6rp) and total S6rp, phosphorylated Akt (p-Akt) and total Akt, and phosphorylated cAMP response element-binding protein (p-CREB). GAPDH was used as a loading control.
effect was markedly suppressed by BAPTA-AM, an intracellular Ca 2ϩ chelator (Fig. 5B) . Importantly, ionomycin was used in this experiment at a concentration (50 nM) that elicited an increase in intracellular Ca 2ϩ comparable to that induced by PGE 2 (data not shown).
To study the possible role of Ca 2ϩ signaling in PGE 2 -induced mTORC1 activation, cells were pretreated with BAPTA-AM prior to PGE 2 stimulation. As shown in Fig. 5C . To further confirm that the G␣ q -coupled EP 1 receptor is involved in PGE 2 -stimulated mTORC1 activation, we utilized a genetic approach to specifically knock down the EP 1 receptor subtype in these cells. Successful gene knockdown was validated by RT-qPCR assessing the levels of EP1 mRNA transcripts in EP1 siRNA-transfected vs. control siRNA-transfected PANC-1 cells (Fig. 5D) (Fig. 5F) .
PGE 2 -induced mTORC1 activation requires both cAMP/ PKA and Ca 2ϩ pathways. Our data suggest that both cAMP/ PKA and Ca 2ϩ pathways are important in mediating PGE 2 -induced activation of mTORC1. To test whether the effects of PGE 2 on mTORC1 activation represent a cell type-specific or a more general phenomenon, we conducted an RT-qPCR screening of EP1, EP2, and EP4 expression in a variety of human cancer cell lines (Fig. 6A) derived from pancreatic 
(by Student's t-test). B:
PANC-1 cells were incubated with agonists for EP4 or EP2 (CAY10580 or butaprost, respectively) for 1 min, and levels of cAMP in cell lysates were determined. *P Ͻ 0.05 (by Student's t-test). (AsPC-1, BxPC-3, Capan-2, HPAF-II, MIA PaCa-2, and PANC-1), prostate (PC-3), breast (MCF-7), and colon (DLD-1 and SW480) cancers, all of which are notably associated with obesity. We found that the responsiveness of mTORC1 activation to PGE 2 correlated well with the coexistence of highly expressed EP 1 (mediating the Ca 2ϩ response) and EP 2 or EP 4 (mediating the cAMP response), as exemplified by PANC-1 and PC-3 cells (Fig. 6A) . In PC-3 cells, PGE 2 robustly stimulated intracellular cAMP (Fig. 6B ) and Ca 2ϩ (Fig. 6C ) levels and the phosphorylation of S6rp (Fig. 6D) . Also, similar to the results in PANC-1 cells, the phosphorylation of S6rp was attenuated by H-89, BAPTA-AM, and rapamycin (Fig. 6, D  and E 2 potentiates the effect of IGF-1 through mTORC1 activation. Our data suggest that, in addition to the canonical insulin/IGF-1-mediated signaling, mTORC1 can be coactivated by the inflammatory PGE 2 pathway, which might potentiate the effects of insulin (and/or IGF-1). To investigate the interaction between these pathways, cells were treated with PGE 2 in combination with IGF-1. As shown in Fig. 7A, PGE 2 enhanced the effect of IGF-1 on the phosphorylation of p70S6K and 4E-BP1 downstream of mTORC1, suggesting reinforcement by the cross talk between the two pathways.
We next investigated phenotypical responses of these signaling events. There is considerable evidence suggesting the contribution of PGE 2 to tumor development in many aspects of the immune and inflammation responses (18, 37) . Since PGE 2 mediates inflammation via cytokine production, we used a human cytokine protein array to measure a panel of cytokines released from PANC-1 cells exposed to PGE 2 , IGF-1, or the combination of the two stimuli. Among the 36 cytokines, chemokines, and acute-phase proteins, we identified two proteins that were especially upregulated by the combination of PGE 2 and IGF-1, PAI-1 (also known as serpin E1), and IL-23, both of which are known to be proinflammatory (Fig. 7B) . Further validation by RT-qPCR showed that IL-23 transcription in PANC-1 cells was promoted by treatment for 24 h with PGE 2 and IGF-1 in combination, but not PGE 2 or IGF-1 alone (Fig. 7C) . Importantly, the upregulation of IL-23 expression was inhibited by rapamycin, confirming that IL-23 production is a consequence of the cross talk between PGE 2 and IGF-1 signaling converging at mTORC1. Together, our studies reveal a novel cross talk between PGE 2 signaling and the IGF-1/ mTORC1 pathway (Fig. 7D) . By regulating cytokine production, this cross talk may be of importance in amplifying the inflammatory response in the tumor microenvironment.
DISCUSSION
Obesity is a contributing factor in the development of a number of cancers, but the mechanisms driving this association remain unclear. Recent in vivo studies from our group and others strongly support the importance of the inflammatory environment in obesity-promoted pancreatic cancer (5, 40) . To further elucidate the molecular mechanisms, we explored a potential link between proinflammatory signaling and hormone/growth factor pathways that are upregulated in obese and insulin-resistant subjects. Specifically, the results presented here identified a signaling cross talk between PGE 2 and mTORC1 pathways in pancreatic cancer cells. Our data show that stimulation of PANC-1 cells with PGE 2 increased the phosphorylation of molecules downstream of mTORC1, including p70S6K, S6rp, and 4E-BP1, indicating that PGE 2 induces activation of mTORC1. Associated with G␣ s , EP 2 and EP 4 are known to mediate PGE 2 -induced intracellular cAMP production. Several previous studies linked a cAMP-dependent pathway to the PI3K/ Akt/mTORC1 signaling module, but the underlying mechanisms vary among diverse cellular systems, implying cell context-specific processes (2, 3, 22) . In epinephrine-stimulated rat skeletal muscle cells, cAMP can activate PI3K/Akt via chelator BAPTA-AM (10 M) for 1 h and then treated with 50 nM ionomycin (an ionophore that raises intracellular Ca 2ϩ levels) for 15 min. C: PANC-1 cells were preincubated with 10 M BAPTA-AM for 1 h and then stimulated with or without PGE2 (1 M) for 15 min. After treatments, cell lysates were collected and subjected to immunoblotting with indicated antibodies. D: PANC-1 cells were transfected with negative control siRNA or EP1 siRNA. After 4 days of incubation, total RNA was extracted from the cells and subjected to quantitative RT-PCR (RT-qPCR) using gene-specific primers for EP1 and ACTB (␤-actin), which was used as an internal reference gene to normalize results. *P Ͻ 0.05 (by Student's t-test). E: PANC-1 cells were transfected with negative control siRNA or EP1 siRNA and then stimulated with or without PGE2 (1 M) for 15 min. After treatment, cell lysates were collected and subjected to immunoblotting with indicated antibodies. GAPDH was used as a loading control. F: PANC-1 cells were pretreated with H-89 (5 M) and BAPTA-AM (10 M), alone or in combination, and then stimulated with or without PGE2 (1 M) for 15 min. After treatments, cell lysates were collected and subjected to immunoblotting with indicated antibodies.
Epac (exchange protein directly activated by cAMP), thereby augmenting the effect of insulin on PI3K/Akt signaling (2). In PANC-1 cells, however, PGE 2 /cAMP-induced activation of mTORC1 seems to be independent of PI3/Akt, as phosphorylation of Akt remained unchanged with PGE 2 or forskolin stimulation. Also, cAMP-activated Epac is known to activate the Ras-associated protein-1 (Rap1)/B-Raf/ERK cascade (6, 27) , which may be an alternative route to mTORC1 activation (33) . However, there was no increase in phosphorylated ERK levels upon PGE 2 treatment in PANC-1 cells. Subsequently, we showed that the effect of PGE 2 or forskolin on mTORC1 activity was attenuated by H-89, suggesting the involvement of PKA, a major target of cAMP. This finding is in agreement with a previous study investigating cAMP-mediated mTORC1 signaling in thyroid cells induced with thyroid-stimulating hormone (51) .
On the basis of the studies using agonist/antagonist for EP 2 and EP 4 , our data suggest that, in PANC-1 cells, the PGE 2 -stimulated cAMP responses are predominantly mediated by EP 4 . Although the significance of EP 4 in vivo remains to be determined, this finding is consistent with the notion that EP 4 plays a major role in colorectal carcinogenesis (36, 42) and with a recent study showing that EP 4 expression is markedly elevated in human pancreatic tumors compared with adjacent benign pancreatic tissues (13) . Also, EP 4 -mediated mTORC1 activation by PGE 2 has been recently demonstrated in colon (8) and prostate (53) cancer cells, reinforcing our findings in pancreatic cancer cells as a common concept, especially in obesity-associated cancers. In those previous reports, however, the significance of cAMP/PKA downstream of EP 4 was not delineated. Importantly, in addition to the EP 4 /cAMP/PKA pathway, we found that PGE 2 -induced mTORC1 activation is also mediated by a Ca 2ϩ -dependent mechanism, which is elicited through the G␣ q -coupled EP 1 receptor, as supported by our results from the EP1 knockdown experiments. Although the role of EP 1 in cancer development is less documented than the role of EP 2 or EP 4 (16) , several studies have identified EP 1 as a critical receptor (20, 52, 55) . Furthermore, on the basis of the maximal inhibition achieved by the combined blockade of both arms of signaling with H-89 and BAPTA-AM, as well as the concurrence of high levels of EP2/EP4 and EP1 in the cell lines (PANC-1 and PC-3) that prominently displayed PGE 2 -activated mTORC1 signaling, we discovered the cooperative roles of cAMP/PKA and Ca 2ϩ pathways in PGE 2 -induced mTORC1 activation. The expression patterns of EP receptors in PANC-1 (high in EP 1 and EP 4 ), PC-3 (high in EP 1 and EP 2 ), and BxPC-3 (high in EP 2 only) cells suggest that, to induce PGE 2 -mediated mTORC1 activation, the functional integrity of both the EP 1 /Ca 2ϩ pathway and the cAMP response is critical, and the latter may be evoked through either EP 2 or EP 4 . Collectively, our studies using pharmacological and genetic approaches demonstrate that PGE 2 -induced mTORC1 activation is mediated by the coordinated operation of the EP 4 /cAMP/PKA and EP 1 /G␣ q /Ca 2ϩ pathways in PANC-1 cells (Fig. 7D) .
Signaling pathways usually interact and cross talk with each other. A precise understanding of these complex networks may reveal critical mechanistic targets for therapeutic intervention devoid of unwanted side effects or resistance. For example, it has been shown in pancreatic cancer cells that the Akt/ mTORC1 pathway mediates a cross talk between insulin receptor and GPCR signaling systems, where insulin can potentiate Ca 2ϩ signaling triggered by G␣ q -coupled receptor agonists (24) . Remarkably, further studies revealed that such cross talk is disrupted by metformin, a widely used antidiabetes drug that negatively regulates mTORC1 through AMP kinase activation, leading to inhibition of pancreatic cancer growth (23) . In the present study we have identified a similar, but reverse, cross talk between PGE 2 -mediated pathways and IGF-1 signaling, converging at mTORC1 and creating a positive reinforcement (Fig. 6D) . Interestingly, PGE 2 and IGF-1 in combination, but not alone, induced IL-23 mRNA transcription in PANC-1 cells, and this effect was abrogated by the mTORC1 inhibitor rapamycin. This finding highlights the significance of the reinforcing cross talk between PGE 2 and IGF-1 signaling through subsequent mTORC1 activation. IL-23, a proinflammatory cytokine, has been shown to promote tumor growth by driving protumorigenic inflammation, as well as impairing T Fig. 7 . Potentiating cross talk between PGE2 and IGF-1 signaling pathways through mTORC1. A: PANC-1 cells were stimulated with IGF-1 (10 ng/ml) in the absence or presence of PGE2 (1 M) for 15 min. After treatments, cell lysates were collected and subjected to immunoblotting with indicated antibodies. B: relative levels of plasminogen activator inhibitor (PAI)-1 and IL-23 in PANC-1 cell supernatants collected after 24 h of indicated treatments were determined using a cytokine array. Values, expressed as signal intensity (arbitrary units), are averages quantified from duplicated spots on the array membrane. C: after 24 h of treatment with PGE2, IGF-1, and rapamycin, relative transcript expression levels of IL-23 in PANC-1 cells were determined by RT-qPCR. *P Ͻ 0.05 (by Student's t-test). D: schematic model showing cross talk between the PGE2 and IGF-1 pathways converging at mTORC1 implicated in obesity-associated tumor promotion. [Ca 2ϩ ]i, intracellular Ca 2ϩ concentration; PI3K, phosphoinositide 3-kinase; eIF4E, eukaryotic translation initiation factor 4E; 4E-BP1, eIF4E-binding protein; p70S6K, ribosomal protein S6 kinase; S6rp, S6 ribosomal protein.
cell-mediated immune surveillance (25, 38) . Also, a recent study suggests that PGE 2 secreted from breast tumor cells, through cAMP/PKA signaling, induces IL-23 expression in the tumor microenvironment, leading to Th17 cell expansion (43) . These novel findings raise the attractive possibility that PGE 2 exerts its protumorigenic properties through regulation of proinflammatory cytokine production by augmentation of mTORC1 function, which is already supported by enhanced IGF-1/Akt signaling under certain conditions (e.g., the obese state and neoplasm). Overall, the signaling cross talk identified above would lead to an exacerbated inflammatory tumor microenvironment and, thereby, contribute to cancer development.
It is noteworthy that we also detected PGE 2 -induced phosphorylation of S6rp in mouse primary PanIN (pancreatic intraepithelial neoplasia) cells, which are precancerous cells isolated from the conditional Kras G12D mouse model of pancreatic cancer (data not shown). These findings suggest that the cross talk between PGE 2 and mTORC1 is not restricted to cancer cells but is also operational in early stages of pancreatic tumor development. Since both inflammation and insulin/ growth hormones are key factors shared by obesity and cancer, this signaling cross talk is highly relevant to obesity-associated cancer, where proinflammatory PGE 2 and systemic high levels of IGF-1 are conducive to tumor development. Given the well-known, potentially harmful cardiovascular side effects of COX-2 inhibitors (32) and feedback mechanisms of resistance associated with mTOR inhibitors (54), a deeper understanding of the molecular pathways involved in this link will facilitate the development of novel efficacious interventions while circumventing adverse effects.
In summary, our data link the PGE 2 signaling to the IGF-1/ Akt/mTORC1 module. The operation of this cross talk strongly supports the hypothesis that inflammation-associated PGE 2 can reinforce the tumor-promoting effects of insulin/IGF-1 signaling. Since both pathways are implicated in obesity, as well as in cancer development, this notion may be of importance in elucidating the connection between obesity and enhanced cancer risk. Ultimately, a detailed understanding of these molecular links may provide novel targets for improved interventions for pancreatic cancer in an increasingly obese population.
